Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Corgentech Cuts Staff To Slow Spending After E2F Decoy Miss

April 21, 2005

By Jennifer Boggs

Agennix Reports Positive NSCLC Data With Talactoferrin, Chemo

April 20, 2005

By Jennifer Boggs

Agennix Reports Positive NSCLC Data With Talactoferrin, Chemo

April 20, 2005

By Jennifer Boggs

Nuvelo Begins Phase III Trial Of Alfimeprase In 'Leg Attack'

April 19, 2005

By Jennifer Boggs

Nuvelo Begins Phase III Trial Of Alfimeprase In 'Leg Attack'

April 19, 2005

By Jennifer Boggs

Acadia Raising $36M Privately For Parkinson's, Schizophrenia Work

April 18, 2005

By Jennifer Boggs

Acadia Raising $36M Privately For Parkinson's, Schizophrenia Work

April 18, 2005

By Jennifer Boggs

Xsira Licenses Clinical-Stage Adenosine-Based Compound

April 15, 2005

By Jennifer Boggs

Xsira Licenses Clinical-Stage Adenosine-Based Compound

April 15, 2005

By Jennifer Boggs

Omeros' Lead Anti-Inflammatory Drug Moves Into Phase III Study

April 14, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...